Developments in targeting calcitonin gene-related peptide
Expert Rev Neurother. 2024 Apr 1:1-9. doi: 10.1080/14737175.2024.2332754. Online ahead of print.ABSTRACTINTRODUCTION: Calcitonin Gene-Related Peptide (CGRP)-targeted therapy has revolutionized migraine treatment since its first approval in 2018. CGRP-targeted therapy includes monoclonal antibodies (mAbs) and gepants, which modulate trigeminal nociceptive and inflammatory responses, alleviating pain sensitization involved in migraine pathogenesis. CGRP-targeted therapy is effective not only for migraine but also for other chronic headache disorders that share the CGRP pathway.AREAS COVERED: The authors review the latest dev...
Source: Expert Review of Neurotherapeutics - April 1, 2024 Category: Neurology Authors: Sawsan Alabbad Nathalia Figueredo Hsiangkuo Yuan Stephen Silberstein Source Type: research
Pharmacotherapy and cognitive bias modification for the treatment of anxiety disorders
Expert Rev Neurother. 2024 Apr 1:1-9. doi: 10.1080/14737175.2024.2334847. Online ahead of print.ABSTRACTINTRODUCTION: Anxiety disorders are characterized by widespread and persistent anxiety or recurrent panic attacks. As a result of their high prevalence, chronicity, and comorbidity, patients' quality of life and functioning are severely compromised. However, several patients do not receive treatment.AREAS COVERED: This review discusses the effectiveness, safety, and limitations of major medications and cognitive bias modification (CBM) for treating anxiety disorders. The possibility of combined treatment is also discusse...
Source: Expert Review of Neurotherapeutics - April 1, 2024 Category: Neurology Authors: Qingyan Kong Buxin Han Source Type: research
Developments in targeting calcitonin gene-related peptide
Expert Rev Neurother. 2024 Apr 1:1-9. doi: 10.1080/14737175.2024.2332754. Online ahead of print.ABSTRACTINTRODUCTION: Calcitonin Gene-Related Peptide (CGRP)-targeted therapy has revolutionized migraine treatment since its first approval in 2018. CGRP-targeted therapy includes monoclonal antibodies (mAbs) and gepants, which modulate trigeminal nociceptive and inflammatory responses, alleviating pain sensitization involved in migraine pathogenesis. CGRP-targeted therapy is effective not only for migraine but also for other chronic headache disorders that share the CGRP pathway.AREAS COVERED: The authors review the latest dev...
Source: Expert Review of Neurotherapeutics - April 1, 2024 Category: Neurology Authors: Sawsan Alabbad Nathalia Figueredo Hsiangkuo Yuan Stephen Silberstein Source Type: research
Pharmacotherapy and cognitive bias modification for the treatment of anxiety disorders
Expert Rev Neurother. 2024 Apr 1:1-9. doi: 10.1080/14737175.2024.2334847. Online ahead of print.ABSTRACTINTRODUCTION: Anxiety disorders are characterized by widespread and persistent anxiety or recurrent panic attacks. As a result of their high prevalence, chronicity, and comorbidity, patients' quality of life and functioning are severely compromised. However, several patients do not receive treatment.AREAS COVERED: This review discusses the effectiveness, safety, and limitations of major medications and cognitive bias modification (CBM) for treating anxiety disorders. The possibility of combined treatment is also discusse...
Source: Expert Review of Neurotherapeutics - April 1, 2024 Category: Neurology Authors: Qingyan Kong Buxin Han Source Type: research
Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder
Expert Rev Neurother. 2024 May;24(5):465-476. doi: 10.1080/14737175.2024.2333394. Epub 2024 Mar 27.ABSTRACTINTRODUCTION: Major Depressive Disorder (MDD) is a mental health issue that significantly affects patients' quality of life and functioning. Despite available treatments, many patients continue to suffer due to incomplete symptom resolution and side effects.AREAS COVERED: This manuscript examines Vortioxetine's role in Major Depressive Disorder (MDD) treatment, highlighting its potential to reshape therapeutic strategies due to its unique Multimodal action and proven broad-spectrum efficacy in multiple depressive doma...
Source: Expert Review of Neurotherapeutics - March 27, 2024 Category: Neurology Authors: Alessandro Cuomo Giovanni Barill à Matteo Cattolico Simone Pardossi Elisa Mariantoni Despoina Koukouna Pietro Carmellini Andrea Fagiolini Source Type: research
Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder
Expert Rev Neurother. 2024 Mar 27:1-12. doi: 10.1080/14737175.2024.2333394. Online ahead of print.ABSTRACTINTRODUCTION: Major Depressive Disorder (MDD) is a mental health issue that significantly affects patients' quality of life and functioning. Despite available treatments, many patients continue to suffer due to incomplete symptom resolution and side effects.AREAS COVERED: This manuscript examines Vortioxetine's role in Major Depressive Disorder (MDD) treatment, highlighting its potential to reshape therapeutic strategies due to its unique Multimodal action and proven broad-spectrum efficacy in multiple depressive domai...
Source: Expert Review of Neurotherapeutics - March 27, 2024 Category: Neurology Authors: Alessandro Cuomo Giovanni Barill à Matteo Cattolico Simone Pardossi Elisa Mariantoni Despoina Koukouna Pietro Carmellini Andrea Fagiolini Source Type: research
